Loss of dental and craniofacial tissues due to disease, injury or genetic disorders negatively affects the quality of life of millions of Americans. Presently, the gold standard in clinical treatment for craniofacial bone defects is autografts and demineralized bone matrix (DBM). Autografts perform exceptionally well, but are known to induce donor site morbidity and DBMs poorly induce regeneration of lost tissue.